-
-
-
-
-
-
-
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
-
-
-
-
-
-
Halozyme Provides 2023 Financial Guidance and Outlook
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Antares Pharma (ATRS)
-
-
-
-
-
-
-
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
-
-
-
-
-
-
-
Halozyme Reports First Quarter 2020 Results
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) to initiate organizational restructuring to halt development activities for PEGPH20 and close its oncology operations
-
100,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

